Skip to content

Debt-to-equity at other companies

Celcuity logo
CelcuityCELC
2.6×+1.4×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
0.1×0.0×
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
0.0×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-0.1×
Tango Therapeutics logo
Tango TherapeuticsTNGX
0.1×-0.1×
LQD
Liquidia CorporationLQDA
0.1×-0.1×

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.46B+300%
Enterprise value$3.29B+304%
P/S324.1×+212×

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s debt-to-equity?
Relay Therapeutics, Inc. (RLAY) reported debt-to-equity of 0× in Q1 2026.
How has Relay Therapeutics, Inc.'s debt-to-equity changed year-over-year?
Relay Therapeutics, Inc.'s debt-to-equity decreased by 24.8% year-over-year, from 0.1× to 0×.
What is the long-term trend for Relay Therapeutics, Inc.'s debt-to-equity?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s debt-to-equity has grown at a 12.3% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.